IPP Bureau
Morepen secures Loratadine approval for export to China
By IPP Bureau - April 01, 2025
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
GE HealthCare launches new advanced CT system
By IPP Bureau - April 01, 2025
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
By IPP Bureau - April 01, 2025
AstraZeneca Pharma India discontinues manufacturing of Imdur
NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals
By IPP Bureau - April 01, 2025
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Akums launches Ripasudil + Timolol combination for glaucoma treatment
By IPP Bureau - April 01, 2025
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
OneSource Specialty Pharma updates on cGMP inspection by USFDA
By IPP Bureau - April 01, 2025
The inspection has concluded with four observations
Lonza implements streamlined operating model
By IPP Bureau - April 01, 2025
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
DKSH Technology acquires Korean life science firm MDxK
By IPP Bureau - March 31, 2025
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Merck seeks FDA approval for subcutaneous pembrolizumab
By IPP Bureau - March 29, 2025
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Curium completes acquisition of Monrol
By IPP Bureau - March 29, 2025
Positions Curium as leading manufacturer of Lu-177 isotope
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
By IPP Bureau - March 29, 2025
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
By IPP Bureau - March 29, 2025
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
WeylChem strengthens custom manufacturing with unified leadership
By IPP Bureau - March 27, 2025
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
By IPP Bureau - March 27, 2025
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia
By IPP Bureau - March 27, 2025
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
